Disease on EC 1.1.1.239 - 3alpha(17beta)-hydroxysteroid dehydrogenase (NAD+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
3alpha(17beta)-hydroxysteroid dehydrogenase (nad+) deficiency
A novel missense (R80W) mutation in 17-beta-hydroxysteroid dehydrogenase type 3 gene associated with male pseudohermaphroditism.
Absent spermatogenesis despite early bilateral orchidopexy in 17-ketoreductase deficiency.
Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency.
Deficiency of 17-ketoreductase presenting before puberty.
Male pseudohermaphroditism due to 17-ketoreductase deficiency: report of a case without gynecomastia and without vaginal pouch.
The nature of the defect in familial male pseudohermaphroditism in Arabs of Gaza.
46, XY Disorders of Sex Development
17beta-hydroxysteroid dehydrogenases: physiological roles in health and disease.
Male pseudohermaphroditism due to 17-ketoreductase deficiency: report of a case without gynecomastia and without vaginal pouch.
The nature of the defect in familial male pseudohermaphroditism in Arabs of Gaza.
[Familial case of male pseudohermaphroditism due to 17-ketoreductase defect: late diagnosis in the "aunt" of a patient with the same defect (author's transl)]
Acne Vulgaris
Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation.
17beta-hydroxysteroid dehydrogenases in human breast cancer.
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Androgens in human breast carcinoma.
Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.
Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells.
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Intracrinology of estrogens and androgens in breast carcinoma.
Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells.
Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism.
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Carcinogenesis
Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia.
Carcinoma
17beta-hydroxysteroid dehydrogenases in human breast cancer.
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Cadmium-induced up-regulation of aldo-keto reductase 1C3 expression in human nasal septum carcinoma RPMI-2650 cells: Involvement of reactive oxygen species and phosphatidylinositol 3-kinase/Akt.
In situ androgen producing enzymes in human prostate cancer.
Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma I. Subcellular distribution and variations of specific enzyme activity.
Carcinoma, Squamous Cell
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Colonic Neoplasms
Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer.
Loss of estrogen inactivation in colonic cancer.
Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer.
Cysts
Immunolocalization of 3beta-HSD and 17beta-HSD in the testis of the spotted ray Torpedo marmorata.
Dermatitis, Atopic
Aldo-Keto Reductase 1C3 Is Expressed in Differentiated Human Epidermis, Affects Keratinocyte Differentiation, and Is Upregulated in Atopic Dermatitis.
Diabetes Mellitus
17beta-hydroxysteroid dehydrogenases: physiological roles in health and disease.
Endometrial Neoplasms
Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Endometriosis
Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis.
Epilepsy
Expression of mRNAs encoding for 17beta-hydroxisteroid dehydrogenase isozymes 1, 2, 3 and 4 in epileptic human hippocampus.
Epilepsy, Temporal Lobe
Expression of mRNAs encoding for 17beta-hydroxisteroid dehydrogenase isozymes 1, 2, 3 and 4 in epileptic human hippocampus.
Gynecomastia
Male pseudohermaphroditism due to 17-ketoreductase deficiency: report of a case without gynecomastia and without vaginal pouch.
Herpes Zoster
Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization.
Hyperandrogenism
KLF15 is a Transcriptional Regulator of The Human 17ss-Hydroxysteroid Dehydrogenase Type 5 Gene. A potential link between regulation of testosterone production and fat stores in women.
Hypospadias
Altered transcription profiles of key-enzymes of androgen biosynthesis in genital skin fibroblasts from patients with 46,XY disorders of sex development (DSD).
Keloid
The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
Leiomyoma
Aromatase and leiomyoma of the uterus.
Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma.
Lung Neoplasms
Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Green tea consumption, genetic susceptibility, PAH-rich smoky coal, and the risk of lung cancer.
Neoplasms
17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation.
17beta-hydroxysteroid dehydrogenases: physiological roles in health and disease.
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases.
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer.
In situ androgen production in human gastric carcinoma--androgen synthesizing and metabolizing enzymes.
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Loss of estrogen inactivation in colonic cancer.
Steroid-converting enzymes in human ovarian carcinomas.
Obesity
17beta-hydroxysteroid dehydrogenases: physiological roles in health and disease.
The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women.
Osteoporosis
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
Local estradiol metabolism in osteoblast- and osteoclast-like cells.
Peroxisomal Disorders
Structure of the gene for the human 17beta-hydroxysteroid dehydrogenase type IV.
Polycystic Ovary Syndrome
Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS).
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome.
Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome.
Polycythemia
Serum testosterone levels and excessive erythrocytosis during the process of adaptation to high altitudes.
Prostatic Hyperplasia
Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases.
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry.
Prostatic Neoplasms
Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.
Development of Potent and Selective Inhibitors of Aldo-Keto Reductase 1C3 (Type 5 17?-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure-Activity Relationships.
Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3).
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Influence of Aldo-keto reductase 1C3 in prostate cancer -a mini review.
New frontiers in androgen biosynthesis and metabolism.
PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.
Tics
Regulation of thyroid hormones on the production of testosterone in rats.